NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









iDEL Therapeutics

iDEL Therapeutics

Private
DortmundHealthcare & Life Scienceshttps://idel-tx.com/

Last Round

Seed

Mar 17, 2026

Total Funding Raised

$20.87M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

iDEL Therapeutics is a biotechnology company developing a pipeline of cancer therapeutics that are delivered directly into the cytosol of tumor cells using a proprietary synthetic shuttle platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

drug deliveryintracellular deliverysynthetic shuttleoncologybiotechnologycytosolic deliverydrug delivery platformundruggable targetsnanobodiessolid tumorspreclinical developmentbiotech platformdrug discoverydelivery techendosomal escape

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

iDEL Therapeutics Comparables

Compare iDEL Therapeutics with similar companies based on industry and business-model similarity.

iDEL Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Xelcis Bio, Inc.
87%
Libera Bio
86%
CyGenica
84%

iDEL Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 17, 2026
SeedMar 17, 2026

Key People

Founding team and executive leadership

Marcus Kostka

CEO

Executive Team

iDEL Therapeutics Investors

Notable investors and investment history

iDEL Therapeutics investors
InvestorRounds
NRW.VentureSeed
KHAN Technology Transfer Fund IISeed
BioMedPartnersSeed
Gründerfonds RuhrSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 17, 2026

    $11M raised in Seed round.

iDEL Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

iDEL Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about iDEL Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersDortmund
Employee Range10
Year Founded2025
Last FundingMar 17, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.